19 days ago
IRON
AnalystsDanielle BrillDanielle Brill's Stock Forecasts
AnalystsDanielle Brill
Analyst Ranking
Top 13%
#637 out of 5116 analysts
Average Return
+15.72%
Win Rate
49%39 out of 79
Risk vs Reward
Poor
Good
Danielle Brill's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Uniqure NvQURE | +1,074.35% | $5.42 | $63.65 | 2024-10-10 - 2025-10-09 | Buy |
Palvella Therapeutics IncPVLA | +231.58% | $31.00 | $102.79 | 2025-07-21 - 2025-11-28 | Strong Buy |
Sage Therapeutics IncSAGE | +149.76% | $70.20 | $175.33 | 2017-05-16 - 2018-05-16 | Buy |
Centessa Pharmaceuticals PLCCNTA | +80.76% | $16.06 | $29.03 | 2025-07-21 - 2025-11-28 | Strong Buy |
Uniqure NvQURE | +79.80% | $15.30 | $27.51 | 2024-12-10 - 2025-11-28 | Strong Buy |
Danielle Brill Analyst Color
Get additional color on Danielle Brill's coverage of popular stocks
a month ago
BBIO
a month ago
ALNY
2 months ago
PVLA
a year ago
SRPT
Danielle Brill's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Palvella Therapeutics IncPVLA | 3 | Strong Buy | $105.00 | +2.15% | Maintains | 19 days ago |
Disc Medicine IncIRON | 6 | Strong Buy | $114.00 | +22.11% | Maintains | 19 days ago |
Neurocrine Biosciences IncNBIX | 7 | Strong Buy | $172.00 | +13.04% | Reiterates | a month ago |
Bridgebio Pharma IncBBIO | 2 | Strong Buy | $80.00 | +11.10% | Reiterates | a month ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $535.00 | +18.56% | Maintains | a month ago |
Immunovant IncIMVT | 5 | Hold | $16.00 | -33.75% | Initiates Coverage On | 2 months ago |
Upstream Bio IncUPB | 1 | Strong Buy | $47.00 | +64.34% | Initiates Coverage On | 2 months ago |
Dianthus Therapeutics IncDNTH | 1 | Strong Buy | $56.00 | +27.33% | Initiates Coverage On | 2 months ago |
Harmony Biosciences Holdings IncHRMY | 8 | Strong Buy | $48.00 | +36.02% | Initiates Coverage On | 4 months ago |
Tectonic Therapeutic IncTECX | 2 | Strong Buy | $64.00 | +198.51% | Initiates Coverage On | 4 months ago |
Centessa Pharmaceuticals PLCCNTA | 1 | Strong Buy | $30.00 | +3.34% | Initiates Coverage On | 4 months ago |
Jefferson Capital IncJCAP | 1 | Strong Buy | $24.00 | +14.45% | Initiates Coverage On | 4 months ago |
Uniqure NvQURE | 6 | Strong Buy | $52.00 | +89.02% | Upgrades | a year ago |
Biomarin Pharmaceutical IncBMRN | 1 | Buy | $79.00 | N/A | Reinstates | a year ago |
Regenxbio IncRGNX | 1 | Buy | $18.00 | N/A | Reinstates | a year ago |
Sarepta Therapeutics IncSRPT | 2 | Buy | $150.00 | N/A | Reinstates | a year ago |
Argenx SeARGX | 7 | Strong Buy | $605.00 | N/A | Reinstates | a year ago |
Xenon Pharmaceuticals IncXENE | 2 | Buy | $50.00 | N/A | Reinstates | a year ago |
Agios Pharmaceuticals IncAGIO | 2 | Buy | $51.00 | N/A | Reinstates | a year ago |
Biogen IncBIIB | 1 | Buy | $283.00 | N/A | Upgrades | 2 years ago |
Passage Bio IncPASG | 5 | Buy | $100.00 | N/A | Maintains | 2 years ago |
Ptc Therapeutics IncPTCT | 6 | Buy | $55.00 | N/A | Maintains | 2 years ago |
Fibrogen IncFGEN | 2 | Buy | $875.00 | N/A | Upgrades | 3 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Vertex Pharmaceuticals IncVRTX | 1 | Hold | N/A | N/A | Initiates Coverage On | 4 years ago |
Acadia Pharmaceuticals IncACAD | 2 | Buy | $35.00 | N/A | Downgrades | 5 years ago |
Global Blood Therapeutics IncGBT | 4 | Hold | $50.00 | N/A | Downgrades | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Zogenix IncZGNX | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Alder Biopharmaceuticals IncALDR | 2 | Buy | $28.00 | N/A | Assumes | 7 years ago |
Sage Therapeutics IncSAGE | 1 | Buy | $82.00 | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.